Bohai Pharmaceuticals Announces Availability of New Investor Fact Sheet

Bohai Pharmaceuticals Group, Inc. (BOPH 1.50, 0.00, 0.00%) , a China-based pharmaceutical company engaged in the production, manufacturing and distribution of Traditional Chinese Medicine in China, today announces the availability of a new online Investor Fact Sheet.

"As part of our goal in keeping investors informed with the latest developments at Bohai, we are releasing our new fact sheet, which we plan to update regularly," said Mr. Hongwei Qu, President and Chief Executive Officer of Bohai Pharmaceuticals Group. "Bohai is able to take advantage of the increasing demand for Traditional Chinese Medicine through our focused corporate growth strategy, which emphasizes quality ingredients and proactive sales and marketing efforts as we leverage the protected manufacturing status and national insurance coverage for certain of our pharmaceutical products."

Mr. Qu continued, "We believe Bohai Pharmaceuticals is a strategically well positioned TCM manufacturer with long term growth potential, and we look forward to providing our investors with updates on our progress over the coming weeks and months."

The Investor Fact Sheet provides a concise overview of Bohai Pharmaceuticals' business model and the company's various opportunities in China's healthcare market, and will prove an important resource for existing shareholders and prospective investors alike.

Suven Life to raise $20 mn by fiscal-end to fund trials

Pharmaceutical company Suven Life Sciences on Wednesday said it will raise $20 million before the end of this fiscal to fund clinical trials of one of its molecules aimed at treating Alzheimer's disease.

"Currently, we have 13 molecules that are aimed for treating central nervous system disorders. One molecule code named '502' has completed the first phase of trials.

"We are looking to enter the second phase of trials by 2011 for which we will require about $20 million," Suven Life Sciences Chairman and CEO Venkat Jasti told reporters here.

The company is looking at issuing convertible bonds which could include FCCBs with a tenure of about 3-5 years to raise the requisite fund.

"We expect success (of the clinical trials) in the next 30 months and that should give us funds for our further activities," he added.

He said that over and above $20 million required for the research of the '502' molecule, the company may need another $30 million to fund its various programmes.

"For the next level of funding, we are counting on the success of '502' molecule. If not then also, we expect success on collaborative efforts with big pharma companies from where we expect milestone payments," Jasti said.

Suven currently has a collaborative efforts with US-based Eli Lily, he said, adding the company is in talks with two other major pharmaceutical companies for collaborative research.

"We hope to establish on more partnership before the end of this year," he said, without disclosing details.

The company which clocked a revenue of Rs 130 crore last fiscal, is expecting 15-20 per cent growth this year, he said.

Progenics Pharmaceuticals Announces Second Quarter 2010 Financial Results

Progenics Pharmaceuticals, Inc. /quotes/comstock/15*!pgnx/quotes/nls/pgnx (PGNX 4.94, +0.05, +1.02%) today announced its results of operations for the second quarter and six months ended June 30, 2010.

Net loss for the second quarter of 2010 was $15.2 million or $0.47, basic and diluted, per share, compared to $15.2 million or $0.49, basic and diluted, per share in the second quarter of 2009. Net loss for the six months ended June 30th was $33.8 million or $1.05, basic and diluted, per share, compared to $17.0 million or $0.55, basic and diluted, per share for the first half of 2009.

Progenics ended the second quarter of 2010 with cash, cash equivalents and marketable securities of $73.6 million, reflecting use of cash of $11.1 million in the quarter, in line with use of cash for the first quarter of 2010, and $22.6 million for the first six months of 2010.

Second quarter revenue totaled $2.3 million, compared to $5.5 million for the same period of 2009, reflecting a decrease in research and development revenue from Wyeth, now a Pfizer Inc. /quotes/comstock/13*!pfe/quotes/nls/pfe (PFE 16.38, -0.04, -0.24%) subsidiary, resulting from the wind down of the Progenics-Wyeth RELISTOR(R) collaboration. For the first half of 2010, Progenics reported revenues of $3.8 million, compared to $26.4 million for the same period in 2009, reflecting decreased research and development revenue and recognition in the first quarter of 2009 of a $15.0 million upfront payment from Ono Pharmaceutical Co., Ltd. (OSE-TYO: 4528), Progenics' collaborator for subcutaneous RELISTOR(R) (methylnaltrexone bromide) in Japan.

Progenics receives royalties from its former collaborator Pfizer on all global net sales of RELISTOR. For the second quarter of 2010, global net sales of RELISTOR, the Company's drug approved for the treatment of opioid-induced constipation in advanced-illness patients, were $3.8 million compared to $4.2 million for the previous quarter and $3.2 million for the second quarter of 2009. U.S. net sales were $2.3 million compared to $2.4 million for the previous quarter and $2.0 million for the same period last year. Ex-U.S. RELISTOR net sales were $1.5 million compared to $1.8 million for the previous quarter and $1.2 million for the same period last year.

Global net sales of RELISTOR for the first half of 2010 were $8.0 million comprised of U.S. and ex-U.S. net sales of $4.7 million and $3.3 million, respectively.

Expenses for the second quarter of 2010 were $17.6 million, $3.8 million less than the $21.4 million for the same period in 2009. For the first half of 2010, expenses totaled $37.7 million, a decrease of $7.2 million from $44.9 million for the same period last year. These decreases in expenses were attributable primarily to lower compensation expenses resulting from a Company-wide decrease in average headcount, reduced manufacturing expenses for PRO 140 and completion of manufacturing for PSMA ADC phase 1 clinical trials, partially offset by an increase in subcutaneous RELISTOR contract manufacturing expenses for the multi-dose pen.

Progenics continues to pursue a range of strategic alternatives for RELISTOR, including licensing, collaboration and/or strategic alliances with worldwide or regional partners, U.S. commercialization of the currently-approved product on its own or with pharmaceutical detailing and sales organizations and/or co-promotion of the franchise with a partner using its own sales force.

"During the second quarter, we made good progress in our discussions with potential partners for the RELISTOR franchise," said Paul J. Maddon, M.D., Ph.D., Founder, Chief Executive and Chief Science Officer. "We finalized the design prototype for a multi-dose pen, another more convenient means of administering RELISTOR and the next planned presentation of the product in its commercial life cycle. We also remain on track to begin pivotal testing of our oral RELISTOR candidate in the second half of 2010."

•